Cite
Better than RECIST and faster than iRECIST: Defining the immunotherapy progression decision score to better manage progressive tumors on immunotherapy
MLA
Belkouchi, Y., et al. Better than RECIST and Faster than IRECIST: Defining the Immunotherapy Progression Decision Score to Better Manage Progressive Tumors on Immunotherapy. Sept. 2022. EBSCOhost, https://doi.org/10.1016/j.annonc.2022.07.159⟩.
APA
Belkouchi, Y., Talbot, H., Lassau, N., Lawrance, L., Farhane, S., Feki-Mkaouar, R., Vibert, J., Cournède, P.-H., Marabelle, A., Ammari, S., & Champiat, S. (2022). Better than RECIST and faster than iRECIST: Defining the immunotherapy progression decision score to better manage progressive tumors on immunotherapy. https://doi.org/10.1016/j.annonc.2022.07.159⟩
Chicago
Belkouchi, Y., Hugues Talbot, N. Lassau, L. Lawrance, S. Farhane, R. Feki-Mkaouar, J. Vibert, et al. 2022. “Better than RECIST and Faster than IRECIST: Defining the Immunotherapy Progression Decision Score to Better Manage Progressive Tumors on Immunotherapy,” September. doi:10.1016/j.annonc.2022.07.159⟩.